作为成年人发作紧急情况的救援疗法的语言下洛拉泽帕姆
Isabella R Lelis1, Gregory L Krauss1
1Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Epilepsy & behavior : E&B
|July 5, 2023
概括
护理人员可以有效地使用舌下洛拉泽帕姆口服缩溶液来治疗长期或重复性发作. 这种方法提供了一种安全而令人满意的替代方案,用于管理的紧急护理.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 对于长时间或重复性发作,存在有限的有效家庭治疗方法.
- 现有的治疗方法,如鼻内二二类药物是昂贵的,而直肠二二是社会上不可接受的.
研究的目的:
- 为了确定护理人员是否可以有效地使用舌下洛拉泽帕姆口服缩溶液来治疗急性发作.
- 评估在家治疗长期和重复性发作时,口服洛拉泽的疗效和安全性.
主要方法:
- 追溯的图表审查和患者/护理人员调查的个人处方下语言洛拉泽帕姆溶液.
- 收集了关于发作模式,抗药物,治疗反应,不良事件和治疗满意度的数据.
- 分析停止,镇静和冷却对治疗准入的影响.
主要成果:
- 在66%的重复性发作患者和70%的长期发作患者中,口下用洛拉泽帕姆有效地阻止了发作.
- 没有报告严重的不良事件;31%的人经历了中度/严重的镇静.
- 报告的高处理满意度 (79%),44%表示制冷有限的访问.
结论:
- 在家用舌下用洛拉泽帕姆溶液治疗有效地中断长期和重复性发作.
- 药物耐受性良好,在家庭用量时没有报告的镇静并发症.
- 患者表达了高度满意度,表明这是紧急管理的有价值的选择.
相关概念视频
Drug Delivery: Enteral Route
518
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
518
Cardiopulmonary Resuscitation IV: Pharmacological Management
28
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
28
Anxiolytic Drugs: Benzodiazepines and Buspirone
919
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
919
CNS Depressants: Barbiturates and Benzodiazepines
346
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
346
Antiepileptic Drugs: Potassium Channel Activators
215
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
215
Sedatives and Hypnotics Drugs: Barbiturates
343
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A...
343


